Barbara G.  McClung net worth and biography

Barbara McClung Biography and Net Worth

Barbara serves as Chief Legal Officer and Corporate Secretary for Caribou Biosciences, where she is responsible for all legal functions, including intellectual property strategy and portfolio management, contracts, corporate transactions, board governance, and employment law. In addition, the company’s human resources function reports to Barbara. Prior to joining Caribou in 2015, she headed the legal functions at Intarcia Therapeutics, Inc. and Cygnus, Inc. Barbara began her career as a patent attorney with E. I. du Pont de Nemours and Company, and then joined Chiron Corporation where she was patent counsel for Chiron’s vaccine division. Barbara is a member of the California, Delaware, and Pennsylvania state bars, and is a registered patent attorney before the United States Patent and Trademark Office. She received a B.A. from the University of California, San Diego an M.A. from the University of Pennsylvania, and a J.D. from the University of Pennsylvania Law School.

How old is Barbara G. McClung?

Ms. McClung is currently 69 years old. There are 5 older executives and no younger executives at Caribou Biosciences. Learn More on Barbara G. McClung's age.

How do I contact Barbara G. McClung?

The corporate mailing address for Ms. McClung and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Barbara G. McClung's contact information.

Has Barbara G. McClung been buying or selling shares of Caribou Biosciences?

Barbara G. McClung has not been actively trading shares of Caribou Biosciences during the past quarter. Most recently, on Tuesday, December 7th, Barbara G. Mcclung bought 6,127 shares of Caribou Biosciences stock. The stock was acquired at an average cost of $2.69 per share, with a total value of $16,481.63. Learn More on Barbara G. McClung's trading history.

Who are Caribou Biosciences' active insiders?

Caribou Biosciences' insider roster includes Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Steven Kanner (Insider), and Barbara McClung (Insider). Learn More on Caribou Biosciences' active insiders.

Barbara G. McClung Insider Trading History at Caribou Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/7/2021Buy6,127$2.69$16,481.63View SEC Filing Icon  
10/20/2021Buy9,219$2.69$24,799.11View SEC Filing Icon  
See Full Table

Barbara G. McClung Buying and Selling Activity at Caribou Biosciences

This chart shows Barbara G Mcclung's buying and selling at Caribou Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Caribou Biosciences Company Overview

Caribou Biosciences logo
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Read More

Today's Range

Now: $1.98
Low: $1.91
High: $2.03

50 Day Range

MA: $2.05
Low: $1.77
High: $2.79

2 Week Range

Now: $1.98
Low: $1.50
High: $8.33

Volume

1,143,775 shs

Average Volume

1,714,250 shs

Market Capitalization

$179.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26